19 September 2024
Physiomics plc
("Physiomics" or the "Company")
Notice of Results and Investor
Presentation via Investor Meet Company
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to announce that it expects to release its
audited results for the financial year ended 30 June 2024 during
the last week of September 2024.
Dr Peter Sargent (CEO) and Dr Jim
Millen (Non-Executive Chairman) will provide a live presentation
relating to the Company's full year results and wider business
update via Investor Meet Company on 7 October 2024 at
noon BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 6
October 2024, 09:00 am BST, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet PHYSIOMICS PLC
via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
Investors who already follow the
Company on the Investor Meet Company platform will automatically be
invited.
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and our
proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.
